Loading quotes...

Forecast

The analysts' average price target is €154.59 (-51.16%). The median is €157.30 (-50.31%).

Buy	20
Hold	9
Sell	1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Cencora relies on specialty pharma as growth driver and raises outlook for Healthcare Solutions

At the Morgan Stanley Global Healthcare Conference, Cencora presented its strategy focused on specialty pharmaceuticals—especially oncology and retinal diseases—and a multi‑stage expansion plan for MSO platforms such as OneOncology and RCA. Management expects adjusted operating earnings growth in Healthcare Solutions of 14.5–15.5% and sees Part B biosimilars, the recovery of World Courier and international 3PL as key growth drivers. In the third quarter, Cencora completed opportunistic share repurchases of $1 billion, repaid a $800 million term loan and reported that short‑term volume shifts at Walgreens are small and already reflected in the outlook. » More on de.investing.com
Cencora: specialty pharmaceuticals remain central growth driver

Cencora said at the Wells Fargo healthcare conference that specialty pharmaceuticals are driving the strong fiscal 2026 and are expected to continue growing in both the physician and hospital businesses. GLP‑1 sales rose in Q3 by 25% to $2.3 billion but remain unprofitable, while OneOncology grew organically from about 1,700 to over 2,300 providers. Management emphasized ongoing investments in oncology, biosimilars and data services and the stability of the relationship with Walgreens despite a small volume shift; an opportunistic share buyback of over $1 billion was also executed. » More on de.investing.com
Cencora confirms annual guidance despite volume shift at Walgreens

Cencora confirmed its adjusted diluted earnings-per-share target for 2026 in a range of $17.75 to $17.95. The stock fell about 4.8% after the report, after Walgreens shifted certain business volumes outside the collaboration effective July 1. Cencora stresses that the main supplier agreement with Walgreens still accounts for the majority of the business and that the volume shift was already reflected in the disclosures on August 5. » More on de.investing.com
Cencora beats Q3 expectations and raises full-year outlook

Cencora reported adjusted EPS of $4.48 for Q3 2026 on revenue of $84.8 billion, surpassing Wall Street estimates. Adjusted operating income rose 17% and adjusted gross profit increased 23%; specialty businesses like OneOncology made a significant contribution. The company raised its full-year adjusted EPS guidance to $17.75–17.95, left its revenue forecast unchanged and reiterated a consolidation of operational growth. The stock rose about 4.3% in premarket trading. » More on de.investing.com
Cencora raises guidance and focuses on specialty markets after OneOncology acquisition

At the Leerink conference Cencora reported US growth of 21% and raised its company forecast by 3.5 points to 11.5–13.5%; expected US operating income growth is now 14–16%. The acquisition of OneOncology, synergies with Retina Consultants of America and an MSO strategy are expected to drive further growth in specialty markets. The sale of MWI to Covetrus yielded $3.5 billion in cash, preferred stock and a 34% stake, and includes a partnership with Walgreens through 2031. Cencora said it is confident it can protect gross profit despite the Inflation Reduction Act through contract design and plans complementary bolt-on acquisitions. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Cencora has already paid €1.55 in dividends. The last payout was in August.

Financials

In the last quarter, Cencora had revenue of €78bn and net profit of €458.55m

(EUR)	September 2026	YoY
Revenue	78bn	9.33%
Gross profit	3.18bn	26.30%
Net profit	458.55m	258.41%
EBITDA	1.04bn	717.46%

Fundamentals

Metric	Value
Market capitalization	€32.68bn
Number of shares	200.85m
52-week high/low	€176.10 - €123.01
Dividend yield	0.65%
Dividends TTM	€2.06
Next dividend	€0.60
Beta	0.56
P/E ratio	19.23
PEG ratio	0.15
P/B ratio	17.93
P/S ratio	0.20

Company profile

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.